Can-Fite to begin Phase III trial of piclidenoson in Israel to treat rheumatoid arthritis

Biotechnology company Can-Fite BioPharma has obtained approval from the Institutional Review Board (IRB) of Barzilai Medical Center in Israel, to begin patient enrolment in the Phase III ACRobat clinical trial of piclidenoson for the treatment of rhe …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news